407 related articles for article (PubMed ID: 33984038)
1. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E;
Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice.
Liu J; Wang J; Yan T; Du D; Qi C; Cao F; Yao N; Yang Y; He Y; Tian Z; Ren D; Zhu L; Chen T; Zhao Y
J Viral Hepat; 2019 Oct; 26(10):1170-1177. PubMed ID: 31177596
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Pan CQ; Duan Z; Dai E; Zhang S; Han G; Wang Y; Zhang H; Zou H; Zhu B; Zhao W; Jiang H;
N Engl J Med; 2016 Jun; 374(24):2324-34. PubMed ID: 27305192
[TBL] [Abstract][Full Text] [Related]
9. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
12. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
13. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Zeng QL; Yu ZJ; Ji F; Li GM; Zhang GF; Xu JH; Chen ZM; Cui GL; Li W; Zhang DW; Li J; Lv J; Li ZQ; Liang HX; Sun CY; Pan YJ; Liu YM; Wang FS
Clin Infect Dis; 2021 Nov; 73(9):e3324-e3332. PubMed ID: 33395488
[TBL] [Abstract][Full Text] [Related]
15. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
17. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
18. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
19. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
